Suicidality

5

Review clinical trials related to Suicidality. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period

In 2020, the world is hit by a global health crisis due to a pandemic following the appearance of Sars-cov-2 or "covid-19". This pandemic was accompanied by a constant fear of contamination and death, relayed by the media. In France, the government proposed in response to the arrival of this virus on French territory. This policy was implemented in different ways over 3 distinct periods: strict containment at the start of the epidemic, then a "lighter" one, and finally a period of social restrictions without between these periods. This policy had a direct and rapid impact on the population's daily routines. Children and adolescents, are more susceptible to psychological trauma, as stress has a direct and psychic development. Studies have shown deleterious impact of the French health situation on the paediatric population. They point to an increase of psychological disorders such as depression and anxiety in the under -20s population, and an increase in suicidal gestures over the 2020-2021 period, with rates remaining higher than in previous years. Suicide is the 2nd leading cause of death in the population aged 15-24. Studies continue to focus on the incidence of suicidal gestures of suicidal gestures and psychological disorders, and few of them examine the factors linked to the increase in these incidences, the traumatic impact or the story of the trajectory. Similarly, the few studies focus only on the population aged 12 and over, and in some cases, do not distinguish between age groups (15-24 or under 20). Investigators believe that the various periods of social restrictions and eco-anxiety caused by the pandemic may have influenced suicidal behaviour in this population. The main objective of this study is to investigate the clinical and socio-economic characteristics of the pediatric population who experienced suicidal behaviors in the Auvergne Rhone Alpes region during the covid 19 pandemic.

Participants needed: 6,500
Trial details
Age: 8-18Biological sex: AllType: InterventionalSponsor: Hospices Civils de LyonUpdated: May 18, 2026Locations: 4
Eligibility criteria

Pre-adolescents (≥ 8 years and < 11 years) [+10]

Admitted to pediatric emergency services or hospitalized in a healthcare facilit... [+6]

Status: Recruiting

Assessing Improvements in Mood and Sleep Trial

This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad moods, and any suicidality. Participants will complete diagnostic interviews, self-report scales, and wear an actigraphy device for the 8 weeks starting at the baseline visit.

Participants needed: 420
Trial details
Age: 55+Biological sex: AllType: InterventionalSponsor: University of PittsburghUpdated: May 19, 2026Locations: 3
Eligibility criteria

Age 55 Years and older [+4]

Active suicide planning with intent or clinical judgement that suicide risk is t... [+9]

Status: Recruiting

Sleep Health in U.S. Marines

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Participants needed: 860
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: San Diego State UniversityUpdated: Apr 16, 2026Locations: 1
Eligibility criteria

Age 18+ [+3]

Planned deployment or training operation lasting 30 days or longer and /or plann... [+2]

Status: Recruiting

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.

Participants needed: 10
Trial details
Phase: Phase 2Age: 25-70Biological sex: AllType: InterventionalSponsor: The University of Texas Health Science Center, HoustonUpdated: Jul 18, 2025Locations: 1
Eligibility criteria

Must have completed written informed consent [+8]

Participants who do not read/speak English [+7]

Status: Recruiting

Nitrous Oxide in the Treatment of Acute Suicidal Ideation

The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.

Participants needed: 85
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: University of ZurichUpdated: Jan 16, 2025Locations: 1
Eligibility criteria

Ability to give written informed consent [+2]

Organic, including symptomatic, mental disorders (F00-F09; lifetime diagnosis) [+15]